Beijing Konruns Pharmaceutical Co Ltd (603590) - Cash Flow Conversion Efficiency

Latest as of September 2025: 0.028x

Based on the latest financial reports, Beijing Konruns Pharmaceutical Co Ltd (603590) has a cash flow conversion efficiency ratio of 0.028x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CN¥96.44 Million ≈ $14.11 Million USD) by net assets (CN¥3.49 Billion ≈ $509.98 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See debt-free asset ratio of Beijing Konruns Pharmaceutical Co Ltd to measure how much of total assets are equity-financed.

Beijing Konruns Pharmaceutical Co Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Beijing Konruns Pharmaceutical Co Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check how high is Beijing Konruns Pharmaceutical Co Ltd's earnings quality to evaluate the quality of earnings relative to operating cash generation.

Beijing Konruns Pharmaceutical Co Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Beijing Konruns Pharmaceutical Co Ltd ranked by their cash flow conversion efficiency.

Company	Cash Flow Conversion Efficiency
Kronos Worldwide Inc NYSE:KRO	-0.010x
Banco da Amazônia S.A SA:BAZA3	-0.160x
Zhejiang Whyis Technology Co.Ltd. SHE:301218	N/A
Newsmax, Inc. NYSE:NMAX	-0.212x
Zhejiang Dehong Automotive SHG:603701	-0.014x
Tianjin Zhong Xin Pharmaceutical Group Corporation Limited STU:2TZ	-0.009x
Shandong Fengyuan Chemical Co Ltd SHE:002805	0.004x
Metalla Royalty & Streaming Ltd V:MTA	0.008x

Annual Cash Flow Conversion Efficiency for Beijing Konruns Pharmaceutical Co Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Beijing Konruns Pharmaceutical Co Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see 603590 market cap.

Year	Net Assets	Operating Cash Flow	Cash Flow Conversion Efficiency	Change
2025-12-31	CN¥3.50 Billion ≈ $511.65 Million	CN¥115.68 Million ≈ $16.93 Million	0.033x	-34.19%
2024-12-31	CN¥3.43 Billion ≈ $501.36 Million	CN¥172.25 Million ≈ $25.20 Million	0.050x	-15.21%
2023-12-31	CN¥3.36 Billion ≈ $492.02 Million	CN¥199.35 Million ≈ $29.17 Million	0.059x	+58.03%
2022-12-31	CN¥3.19 Billion ≈ $466.82 Million	CN¥119.69 Million ≈ $17.51 Million	0.038x	+65.64%
2021-12-31	CN¥3.13 Billion ≈ $458.10 Million	CN¥70.91 Million ≈ $10.38 Million	0.023x	+19.61%
2020-12-31	CN¥3.08 Billion ≈ $451.28 Million	CN¥58.41 Million ≈ $8.55 Million	0.019x	-80.28%
2019-12-31	CN¥2.73 Billion ≈ $399.19 Million	CN¥262.00 Million ≈ $38.34 Million	0.096x	-9.45%
2018-12-31	CN¥2.48 Billion ≈ $363.01 Million	CN¥263.11 Million ≈ $38.50 Million	0.106x	-46.86%
2017-12-31	CN¥1.36 Billion ≈ $198.32 Million	CN¥270.49 Million ≈ $39.58 Million	0.200x	+17.77%
2016-12-31	CN¥874.92 Million ≈ $128.03 Million	CN¥148.26 Million ≈ $21.70 Million	0.169x	-39.63%
2015-12-31	CN¥683.27 Million ≈ $99.98 Million	CN¥191.80 Million ≈ $28.07 Million	0.281x	+4.59%
2014-12-31	CN¥488.02 Million ≈ $71.41 Million	CN¥130.98 Million ≈ $19.17 Million	0.268x	-48.62%
2013-12-31	CN¥313.45 Million ≈ $45.87 Million	CN¥163.72 Million ≈ $23.96 Million	0.522x	--

About Beijing Konruns Pharmaceutical Co Ltd

SHG:603590 China Biotechnology

Market Cap

$692.46 Million

CN¥4.73 Billion CNY

Market Cap Rank

#10418 Global

#2744 in China

Share Price

CN¥29.76

Change (1 day)

+0.88%

52-Week Range

CN¥28.13 - CN¥62.00

All Time High

CN¥65.00